Entrectinib: an Orally Available, Selective Tyrosine Kinase Inhibitor for the Treatment of NTRK, ROS1, and ALK Fusion-Positive Solid Tumors
DOAJ (DOAJ Directory of Open Access Journals)（2018）
关键词
entrectinib,lung cancer,NSCLC,TRK,ALK,ROS1
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要